IP Library Granted Patent US 10,100,279
Granted Patent B2
US 10,100,279 · App. 14/763,397 · Granted Oct 16, 2018

In vitro production of medial ganglionic eminence precursor cells

Inventors: Cory R. Nicholas (San Francisco, CA); John L. Rubenstein (San Francisco, CA); Arnold R. Kriegstein (Mill Valley, CA); Arturo Alvarez-Buylla (Woodside, CA)
Assignee: The Regents of the University of California
C12N5/0618C12N5/0619C12N2500/90C12N2501/13C12N2501/41C12N2501/727C12N2501/999C12N2506/02C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,100,279
App. No.
14/763,397
Granted
Oct 16, 2018
Kind
B2
Abstract

Methods and systems for generating MGE precursor cells in vitro as well as compositions of enriched MGE precursor cells are provided. The methods and systems provide efficient production of MGE precursors. The methods and systems disclosed herein provide functional MGE precursors which differentiate into functional GABAergic interneurons.

Claims (23)

1. A method of providing a cell culture enriched for primate medial ganglionic eminence (MGE) precursor cells, the method comprising:

providing primate pluripotent stem cells in a serum-free culture medium;

introducing to the culture medium factors comprising:

a) an activator of the sonic hedgehog (shh) pathway;

b) a SMAD inhibitor;

c) a wnt pathway inhibitor; and

d) a neural inducing supplement,

wherein the serum-free culture medium lacks Knockout Serum Replacement (KSR);

wherein the introduction of a) through d) provides a cell culture enriched in MGE precursor cells compared to a cell culture untreated by this combination of factors, and wherein the MGE precursor cells express NKX2.1 and do not detectably express PAX6.

2. The method of claim 1 , wherein the primate pluripotent stem cells are human induced pluripotent stem cells.

3. The method of claim 1 , wherein the primate pluripotent stem cells are human embryonic stem cells.

4. The method of claim 1 , wherein the primate pluripotent stem cells are cultured in the absence of a feeder layer.

5. The method of claim 1 , wherein the primate pluripotent stem cells are cultured in suspension.

6. The method of claim 1 , wherein the culture medium comprises two or more inhibitors of SMAD.

7. The method of claim 1 , wherein the culture medium further comprises an apoptosis inhibitor.

8. The method of claim 7 , wherein the inhibitor of apoptosis is an inhibitor of Rho-associated kinase (ROCK).

9. The method of claim 1 , further comprising adding a cryoprotectant to the cell culture enriched in MGE precursor cells.

10. The method of claim 1 , wherein the primate pluripotent stem cell culture provided is genetically modified.

11. The method of claim 10 , wherein the primate pluripotent stem cell culture provided expresses a fluorescent protein.

12. The method of claim 1 , further comprising isolating the MGE precursor cells from the cell culture.

13. The method of claim 12 , wherein the isolating comprises using mechanical means.

14. The method of claim 12 , wherein the isolating comprises using an affinity reagent that binds to the MGE precursor cells.

15. The method of claim 12 , wherein the isolating comprises using enzymatic means.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2016
From: NICHOLAS, CORY R.; RUBENSTEIN, JOHN L.; KRIEGSTEIN, ARNOLD R.; ALVAREZ-BUYLLA, ARTURO
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 039273/0962 →
CONFIRMATORY LICENSE Recorded Sep 30, 2015
From: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036732/0589 →
Continuity (2)
Provisional Application 61783594 · Mar 14, 2013
Related Publication 20150361393A1 · Dec 17, 2015
Cited By (15)
US 12,241,084 US 12,241,090 US 12,258,584 US 12,281,334 US 12,297,457 US 12,343,359 US 12,379,372 US 12,385,009 US 12,414,967 US 12,421,500 US 12,428,622 US 12,497,597 US 12,534,709 US 12,600,943 US 12,729,368